Objective measures of adherence for later-stage ART failure in resource limited settings
在资源有限的环境中对后期 ART 失败的依从性进行客观测量
基本信息
- 批准号:10012880
- 负责人:
- 金额:$ 8.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-14 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAdherenceAgeAnti-Retroviral AgentsBiological AssayBloodCD4 Lymphocyte CountClinicalCounselingDataExposure toFailureFundingGeneticGenotypeGrowthHIVHairIngestionIntervention StudiesMeasuresMethodologyModelingMonitorNew AgentsOutcomeParticipantPatient Self-ReportPatientsPatternPharmaceutical PreparationsPharmacologyPharmacy facilityPlasmaProtease InhibitorRecommendationRegimenResearch DesignResistanceResourcesSamplingScalp structureSocial DesirabilitySpecimenSpottingsSubgroupTenofovirTestingTimeTreatment FailureUnited States National Institutes of HealthUrineViralViral Load resultantiretroviral therapybaseclinical applicationcohortcostdata formatdesignexperienceimprovedimproved outcomeinnovationlow and middle-income countriesmonitoring devicenovelpillpoint of careprospectivepublic health relevanceresponsesexsuccesstherapy adherenceviral resistancevirology
项目摘要
PROJECT SUMMARY/ ABSTRACT
Strategies to prolong the durability of ART in low-and-middle income countries (LMICs) are important. With the
new recommendation for dolutegravir to be used for all people living with HIV (PLHIV) globally, first-line ART
now contains an agent with a high genetic barrier to resistance for the first time. Second-line ART still includes
protease inhibitors (PIs) which have high genetic barriers to resistance like dolutegravir. First-line ART failure
in the current era triggers enhanced adherence counseling, more frequent viral loads, and a switch to second-
line ART if unsuccessful. Second-line ART failure in LMIC then requires expensive and difficult-to-access
resistance testing and/or third-line ART and, therefore, unraveling the contribution of inadequate adherence to
ART failure in LMICs, especially in the era of regimens with high genetic barriers to resistance, is critical.
The AIDS Clinical Trials Group (ACTG) A5288 (MULTI-OCTAVE) study is an unprecedented
prospective interventional study that evaluated strategies to treat PLHIV experiencing virologic failure on
second-line regimens in LMIC. Self-reported adherence was not associated with virologic failure in the
study, likely revealing the limitations of self-report. Importantly, A5288 chose to integrate an objective
adherence metric into their study design by collecting hair samples for antiretroviral (ARV) levels, a
methodology we pioneered at UCSF. However, A5288 requires independent funding to assay the hair
samples (as sought in this R03) collected in the study to retrospectively assess the contribution of adherence
to failure. Moreover, although performing hair levels is not practical in routine clinical settings, our group and
others have recently developed and validated a practical, low-cost, real-time urine-based objective
adherence metric, which measures tenofovir use over the short-term.
We plan in this proposal to exploit a novel application of hair analysis by segmenting one half of each
sample collected in A5288 into a proximal short segment (reflecting 1 week of exposure) and the other half into
a longer segment to reflect longer-term (6 weeks) of exposure to examine both short-term and long-term
metrics of adherence in relationship to virologic outcomes and resistance in LMIC. We will also examine the
relationship between short-and long-term hair measures to determine if “white coat” adherence occurred in this
study. The use of objective adherence metrics in this large and well-characterized cohort of ART failure in
LMIC will define the degree of adherence required to maintain virologic success on regimens with high
genetic barriers to resistance (of particular import now that the new agent for first-line therapy globally is
dolutegravir). Moreover, the novel design of this relatively low-cost proposal, leveraging data and samples
already collected in an NIH-funded study, along with segmental hair analysis, will provide formative data on
how to inform the use of practical short-term urine-based point-of-care adherence assays (which will be widely
available within the year) to improve outcomes in resource-limited settings.
项目总结/摘要
在低收入和中等收入国家,延长抗逆转录病毒疗法持久性的战略十分重要。与
多替拉韦用于全球所有艾滋病毒感染者(PLHIV)的新建议,一线ART
现在首次包含了一种具有高遗传抗性屏障的药剂。二线ART仍包括
蛋白酶抑制剂(PI),其具有高遗传抗性屏障,如度鲁特韦。一线ART失败
在当前的时代触发加强坚持咨询,更频繁的病毒载量,并切换到第二-
如果不成功,则行ART。LMIC的二线ART失败则需要昂贵且难以获得的
耐药性测试和/或三线ART,因此,揭示了不充分遵守的贡献
在中低收入国家,特别是在耐药基因屏障高的时代,ART失败是至关重要的。
艾滋病临床试验组(ACTG)A5288(MULTI-OCTAVE)研究是一项前所未有的
一项前瞻性干预性研究,评估了治疗病毒学失败的PLHIV的策略,
二线治疗方案。自我报告的依从性与病毒学失败无关。
研究,可能揭示了自我报告的局限性。重要的是,A5288选择将物镜
通过收集头发样本进行抗逆转录病毒(ARV)水平检测,
我们在加州大学旧金山分校开创的方法。然而,A5288需要独立的资金来分析头发,
研究中采集的样本(如本R 03所述),以回顾性评估依从性的贡献
要失败的此外,尽管在常规临床环境中进行毛发水平测定是不实际的,但我们的小组和
其他人最近开发并验证了一种实用的、低成本的、实时的基于尿液的目标
依从性指标,衡量短期内替诺福韦的使用情况。
我们计划在这个建议,以开拓一个新的应用程序的头发分析分割一半,每个
在A5288中收集的样本进入近端短段(反映1周的暴露),另一半进入
反映长期(6周)暴露的较长部分,以检查短期和长期
与病毒学结果和LMIC耐药性相关的依从性指标。我们亦会研究
短期和长期毛发测量之间的关系,以确定“白色被毛”粘附是否发生在这个
study.在这个大型且特征良好的ART失败队列中使用客观依从性指标,
LMIC将定义维持高风险方案的病毒学成功所需的依从性程度。
耐药性的遗传障碍(特别重要的是,现在全球一线治疗的新药物是
dolutegravir)。此外,这种设计新颖的相对低成本的建议,利用数据和样本,
已经在NIH资助的一项研究中收集的数据,沿着部分毛发分析,将提供以下方面的形成性数据:
如何通知使用实际的短期基于尿液的护理点依从性测定(这将被广泛
年内提供),以改善资源有限情况下的成果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Monica Gandhi其他文献
Monica Gandhi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Monica Gandhi', 18)}}的其他基金
Unraveling the intersection of substance use, inflammation, and HIV via hair levels
通过头发水平揭示物质使用、炎症和艾滋病毒的交叉点
- 批准号:
10761023 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines
评估 HIV 状态对 mRNA COVID-19 疫苗免疫反应的影响
- 批准号:
10481408 - 财政年份:2022
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines
评估 HIV 状态对 mRNA COVID-19 疫苗免疫反应的影响
- 批准号:
10581700 - 财政年份:2022
- 资助金额:
$ 8.05万 - 项目类别:
The HIV Nexus Scholars Program: A Research Education Program for Early-Stage Investigators Working at the Intersection of Biomedical, Social/Behavioral, and Clinical Science
HIV Nexus 学者计划:针对生物医学、社会/行为和临床科学交叉领域的早期研究人员的研究教育计划
- 批准号:
10313585 - 财政年份:2021
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
大型城市安全网 HIV 诊所中 HIV 和 COVID-19 之间相互作用的评估
- 批准号:
10169797 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
大型城市安全网 HIV 诊所中 HIV 和 COVID-19 之间相互作用的评估
- 批准号:
10462510 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
尿液替诺福韦即时检测可识别需要 ART 依从性支持的患者
- 批准号:
10211122 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
尿液替诺福韦即时检测可识别需要 ART 依从性支持的患者
- 批准号:
9983237 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
大型城市安全网 HIV 诊所中 HIV 和 COVID-19 之间相互作用的评估
- 批准号:
10669735 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
大型城市安全网 HIV 诊所中 HIV 和 COVID-19 之间相互作用的评估
- 批准号:
10224038 - 财政年份:2020
- 资助金额:
$ 8.05万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 8.05万 - 项目类别:
Fellowship Programs